It is enriched in elderly patients, with approximately 40% having grade II/III glioma, suggesting TERT’s correlation with shorter overall survival as a key pathological player and therapeutic target (Chamberlain and Sanson, 2015; Mosrati et al., 2015; Spiegl-Kreinecker et al., 2015; Yang et al., 2016; Yuan et al., 2016). This evidence concerns the gene TERT and central nervous system cancer.